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Malignant mesothelioma (MM) is a tumor arising from mesothelium. MM patients’
survival is poor. The polyphenol 4′,5,7,-trihydroxyflavone Apigenin (API) is a
“multifunctional drug”. Several studies have demonstrated API anti-tumoral effects.
However, little is known on the in vitro and in vivo anti-tumoral effects of API in MM.
Thus, we analyzed the in vitro effects of API on cell proliferation, cell cycle regulation, pro-
survival signaling pathways, apoptosis, and autophagy of human and mouse MM cells.
We evaluated the in vivo anti-tumor activities of API in mice transplanted with MM #40a
cells forming ascites. API inhibited in vitro MM cells survival, increased reactive oxygen
species intracellular production and induced DNA damage. API activated apoptosis but
not autophagy. API-induced apoptosis was sustained by the increase of Bax/Bcl-2 ratio,
increase of p53 expression, activation of both caspase 9 and caspase 8, cleavage of
PARP-1, and increase of the percentage of cells in subG1 phase. API treatment affected
the phosphorylation of ERK1/2, JNK and p38 MAPKs in a cell-type specific manner,
inhibited AKT phosphorylation, decreased c-Jun expression and phosphorylation, and
inhibited NF-κB nuclear translocation. Intraperitoneal administration of API increased
the median survival of C57BL/6 mice intraperitoneally transplanted with #40a cells and
reduced the risk of tumor growth. Our findings may have important implications for the
design of MM treatment using API.
Keywords: cancer, mesothelioma, apigenin, apoptosis, polyphenol
INTRODUCTION
Malignant mesothelioma (MM) is a tumor arising from mesothelial cells of the serous membranes,
most commonly involving the pleural and peritoneal spaces (Antman, 1993). MM are of
epithelioid, sarcomatoid, and biphasic types (Inai, 2008). The development of MM has been linked
to the exposure to asbestos which causes genotoxic and non-genotoxic damages (Carbone et al.,
2012; Izzi et al., 2012a). Abnormal activation of the AP-1/TNF-α/NF-κB autocrine pathway in
DNA-damaged mesothelial cells increases their survival and promotes uncontrolled cell growth
(Carbone et al., 2012). Mesothelial cells activate inflammation by releasing reactive oxygen species
(ROS), nitrogen species (RNS), and cytokines. Inflammatory cells are responsible during the
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frustrated phagocytosis of asbestos fibers for the free radicals
mediated mesothelial cell injury as well (Branchaud et al., 1993;
Carbone et al., 2012). In addition, the chronic inflammation and
the poor response to therapeutics might be due to the ability of
MM cells to subvert host immune response (Branchaud et al.,
1993; Kim et al., 2006; Izzi et al., 2009; Chéné et al., 2016).
Despite the knowledge of MM carcinogenesis, MM patients’
survival is poor, and it was slowly improving in the last decades
(Howlader et al., 2009). The therapeutic strategies for the
treatment of malignant pleural mesothelioma are referred to as
‘life-extending treatments’ (Favoni and Florio, 2011). Intra serous
sac administration of drugs in the peritoneal or pleural space
might improve the treatment of MM avoiding or diminishing
therapy side effects and increasing drugs’ bioavailability. Taking
into account the poor outcome and toxicity of chemotherapy,
novel approaches based on targeting abnormal activated signaling
pathways in MM cells were employed to improve MM patients
survival. Preclinical trials have used a second generation of
drugs including inhibitors of mTOR, folate, receptor tyrosine
kinase and ciclooxygenase, while clinical trials have been carried
out using chemotherapy with proteasome, mTOR and histone
deacetylases inhibitors (Favoni and Florio, 2011). However,
although single targeted therapies have shown to ameliorate
the quality of patients life and their survival and the use of
new generation of folate inhibitors alone or in combination
with platinum derivatives showed promising results, the patients
absolute response rate was insufficient as compared to other
tumors (Favoni and Florio, 2011).
4′,5,7,-trihydroxyflavone, commonly called Apigenin, is a
flavonoid contained in fruits and vegetables such as orange,
grapefruit, onion, parsley, basil, celery, tea leaf, licorice root,
wheat sprouts (Shukla and Gupta, 2010; Izzi et al., 2012b;
Benvenuto et al., 2016c; Grosso et al., 2016; Sung et al., 2016;
Ganai, 2017). Apigenin has been demonstrated to have anti-
tumoral effects due to its ability to inhibit the growth of a
variety of human cancer cell lines in vitro (Shukla and Gupta,
2010; Masuelli et al., 2011; Bao et al., 2013; Tong and Pelling,
2013; Chen et al., 2014; Lee et al., 2014; Wu et al., 2014; Liu
et al., 2015; Seo et al., 2015; Shi et al., 2015; Shukla et al.,
2015; Kim et al., 2016; Sung et al., 2016; Xu et al., 2016; Lim
et al., 2016; Ganai, 2017). Apigenin induces a G0/G1 and G2/M
cell cycle arrest through suppression of cyclin B-associated cdc2
activity and phosphorylation of Rb, induction of p21 and p27 and
down-regulation of cyclin D1, D3, and cdk4 (Lepley and Pelling,
1997; Yin et al., 2001; Ujiki et al., 2006; Shukla and Gupta, 2007;
Hussain et al., 2010). Apigenin was reported to activate both the
intrinsic and extrinsic apoptotic pathways in cancer cells (Chen
et al., 2014; Lee et al., 2014; Seo et al., 2015; Shi et al., 2015;
Sung et al., 2016) and in few experimental models to induce
simultaneous autophagy (Sung et al., 2016). Several signaling
pathways were shown to be inhibited by apigenin in cancer cells
(Lepley and Pelling, 1997; Yin et al., 2001; Ujiki et al., 2006; Shukla
and Gupta, 2007; Hussain et al., 2010; Shukla and Gupta, 2010;
Masuelli et al., 2011; Bao et al., 2013; Tong and Pelling, 2013;
Chen et al., 2014; Lee et al., 2014; Wu et al., 2014; Liu et al.,
2015; Seo et al., 2015; Shi et al., 2015; Shukla et al., 2015; Sung
et al., 2016; Kim et al., 2016; Lim et al., 2016; Xu et al., 2016;
Ganai, 2017). Apigenin was able to inhibit the phosphorylation
of EGFR, ErbB2, and mitogen activated protein (MAP) kinase
and the activity of PI3K/AKT (Masuelli et al., 2011; Lim et al.,
2016). Apigenin has also been shown to limit cancer cells invasion
by inhibiting FAK/Src signaling and tumor angiogenesis (Fang
et al., 2007; Franzen et al., 2009). Apigenin limited the activation
of the Wnt/β-catenin signaling pathway (Liu et al., 2015; Xu
et al., 2016), and the activity of NF-κB (Wu et al., 2014; Shukla
et al., 2015). In addition, apigenin has been shown to block the
phosphorylation of c-Met and its downstream effectors (Kim
et al., 2016).
To our knowledge no studies were performed to analyze the
effect of apigenin on signal transduction pathways activated in
MM cells and on the in vivo growth of MM cells. Thus, in
this report we evaluated for the first time the in vivo effect of
intratumoral administration of API in a mouse model in which
MM cells form ascites after transplantation in the peritoneal
cavity. In addition, we evaluated in vitro effects of API on cell
growth, cell cycle regulation, pro-survival signaling pathways,
apoptosis and autophagy in human and mouse MM cell lines.
MATERIALS AND METHODS
Reagents
DMSO, 4′,5,7,-trihydroxyflavone (Apigenin, API),
Sulforhodamine B (SRB), Hoechst 33342 and DAPI were
purchased from Sigma–Aldrich (Milano, Italy). Antibodies
against AKT, phospho-AKT, p38 and phospho-p38, JNK and
phospho-JNK, caspase 9, caspase 8, c-Jun, phospho-c-Jun,
IκBα, and phospho-IκBα were obtained from Cell Signaling
Technology (Boston, MA, United States). Antibodies against
Bax, Bcl-2, and γ-H2AX were obtained from BD Pharmigen
(BD Biosciences, San Jose, CA, United States). Antibodies
against p53, PARP-1, ERK1/2 (C-14), phospho-ERK (E-4),
NF-κB (p65) were obtained from Santa Cruz Biotechnology
(Santa Cruz, CA, United States). Antibodies against Beclin-1
and p62/SQSTM1 were obtained from Abcam (Cambridge,
United Kingdom). The anti-LC3 antibody was purchased from
Novus Biologicals (Littleton, CO, United States). Peptide antisera
to human EGFR and ErbB2 receptors have previously been
characterized for detection specificity by immunohistochemistry
and immunoblotting (Fedi et al., 1994; Alimandi et al., 1995; Bei
et al., 1999).
Goat anti-mouse IgG Alexa fluor-488-conjugated secondary
antibody was purchased from Invitrogen (Milano, Italy). The
rabbit polyclonal antibodies against actin and tubulin and
goat anti-mouse or the anti-rabbit IgG peroxidase-conjugated
secondary antibodies were obtained from Sigma-Aldrich.
Cell Lines and Treatments
Human MM cell lines [MM-F1 (fibromatous), MM-B1
(biphasic), and H-Meso-1 (epithelioid)] and the murine MM cell
line #40a were maintained in DMEM (Dulbecco’s modified Eagle’s
medium) containing 10% fetal bovine serum, 100 U/ml penicillin
and 100 µg/ml streptomycin (complete medium). The cells were
grown at 37◦C in a humidified incubator with an atmosphere
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of 5% CO2. Isolation of the murine mesothelioma 40-cell line
was previously described by Goodglick et al., 1997. The #40a
cell line is derived from the 40-cell line after two passages in
the peritoneal cavity of C57BL/6 mice following administration
of pristane one week before cells transplant. These passages
allow the selection of cells which reproducibly form ascites when
intraperitoneally injected in the mice. H-Meso-1 cells have an
epithelial morphology, while MM-B1 and MM-F1 cells have
biphasic and sarcomatous features, respectively (Palumbo et al.,
2008). The 40-cell line has an epithelial morphology (Goodglick
et al., 1997). API was dissolved in DMSO. For the treatments, the
cells were incubated for the indicated times in the presence of
API (dose range: 6.25–100 µM) or the vehicle (DMSO ≤ 0.1%).
Sulforhodamine B (SRB) Assay
Cells were seeded at 5× 103/well in 96-well plates and incubated
at 37◦C to allow cell attachment. After 24 h, the medium was
changed and the cells were treated with API or DMSO and
incubated for 24 h, 48 h, 72 h at concentrations of 6.25–12.5–25–
50–100 µM. The cells were then fixed with cold trichloroacetic
acid (final concentration 10%) for 1 hour at 4◦C. After four
washes with distilled water, the plates were air-dried and stained
for 30 min with 0.4% (wt/vol) SRB in 1% acetic acid. After four
washes with 1% acetic acid to remove the unbound dye, the
plates were air-dried, and cell-bound SRB was dissolved with
200 µl/well of 10 mM unbuffered Tris base solution. The optical
density (O.D.) of the samples was determined at 540 nm with a
spectrophotometric plate reader. The percentage survival of the
cultures treated with API was calculated by normalizing their
O.D. values to those of control cultures treated with DMSO
(Benvenuto et al., 2016b; Masuelli et al., 2017). The experiments
were performed in triplicate and repeated three times.
Trypan Blue Exclusion Test
For trypan blue exclusion test, cells were seeded at 5 × 104/well
in 24-well plates and incubated at 37◦C to allow cells attachment.
After 24 h, the medium was changed and the cells were treated
with API or DMSO and incubated for 24 h, 48 h, 72 h at
concentrations of 6.25–12.5–25–50–100 µM. After 24 h, 48 h,
and 72 h, adherent as well as suspended cells of each well were
harvested and stained with trypan blue (Sigma–Aldrich, Milan,
Italy) and counted with an optic microscope (Strober, 2001).
The experiments were repeated three times. Percentage of cells
death was determined compared to the total number of cells
(Benvenuto et al., 2015).
Fluorescent Measurement of ROS
Dichlorofluorescin diacetate (DCF-DA) was used to detect ROS
production in cells. Briefly, 2.5 × 105 cells were seeded into 6-
well plates and incubated at 37◦C to allow cell attachment before
treatment. After two washings with PBS, cells were incubated
with 10 µM 2’,7’-dichlorofluorescein diacetate (Sigma–Aldrich,
Milan, Italy) in PBS at 37◦C and 5% CO2 in the dark for
30 min (Masuelli et al., 2016). After two washings, cells were
treated with API (6.25–100µM) or DMSO in serum-free medium
and incubated at 37◦C and 5% CO2 in the dark for different
times (15 min-4 h). Then, adherent cells and suspended cells
were harvested, centrifuged at 1250 rpm for 10 min, and
seeded in 96-well plates (100 µl per well). Fluorescence intensity
was measured after 15 and 30 min and 1 and 4 h using a
spectrophotometric plate reader at an excitation wavelength
of 495 nm and an emission wavelength of 535 nm. Because
the highest level of fluorescence was detected at 30 min and
then decreased back to the level of the control after 1 h of
stimulation (data not shown), this experimental time was chosen
for subsequent experiments.
FACS Analysis
Asynchronized, log-phase growing cells (60% confluent,
approximately 2.5 × 105/well in 6-well plates) were treated with
API (6.25–12.5–25–50–100 µM) or DMSO in complete culture
medium. After 48 h adherent as well as suspended cells were
harvested, centrifuged at 1500 rpm for 10 min and washed twice
with cold phosphate-buffered saline (PBS). The cell pellets were
re-suspended in 70% ethanol and incubated for 1 h at –20◦C.
The cells were then washed twice with cold PBS, centrifuged
at 1500 rpm for 10 min, incubated for 1 h in the dark with
propidium iodide (25 µg/ml final concentration in 0.1% citrate
and 0.1% Triton X-100) and analyzed by flow cytometry using a
FACSCalibur cytometer with CellQuest software (Masuelli et al.,
2014).
Preparation of Cell Lysates and Western
Blotting
Approximately 1 × 106 cells were seeded in 100-mm tissue
culture dishes 24 h prior to the addition of 50 µM API or vehicle.
After 24 h of incubation, the cells were harvested, washed twice
with cold PBS and lysed in RIPA lysis buffer (Triton X-100
1%, SDS 0.1%, NaCl 200 mM, Tris HCl 50 mM pH 7.5, PMSF
1 mM, and NaOV 1 mM). After 30 min at 4◦C, the mixtures
were centrifuged at 12000 g for 15 min and the supernatants
were analyzed by Western blotting. For Western blotting analysis,
50 µg of cell lysates were resolved in 10% SDS-PAGE and
then transferred to nitrocellulose membranes. After blocking,
the membranes were incubated with specific primary antibodies
at 1–2 µg/ml concentrations overnight at 4◦C. After being
washed, the filters were incubated with goat anti-mouse or
anti-rabbit IgG, peroxidase-conjugated antibodies and developed
by chemiluminescence as previously described (Masuelli et al.,
2017). A densitometric analysis of autoradiographic bands was
performed with Image J software (National Institutes of Health,
United States) after blot scanning.
Immunofluorescence
Cells were seeded at 4 × 104 cells/well in 8-well chamber slides
and, after 24 h, they were treated with 50 µM API, or with
the vehicle. After 24 h, the cells were fixed in 4% formaldehyde
for 10 min, washed and fixed in methanol for 5 min at –20◦C,
then washed again and incubated with specific primary antibody
against NF-κB for 1 h at room temperature. After additional
washings, the cells were labeled with a goat anti-mouse IgG Alexa
fluor-488-conjugated secondary antibody for 30 min (Masuelli
et al., 2012). After a third washing, the cells were incubated with
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0.1 µg/ml DAPI and mounted under a cover slip with glycerol.
The cells were observed with an Olympus BX51 microscope.
In Vivo Treatment of C57BL/6 Mice
Intraperitoneally Administered with API
and Transplanted with MM #40a Cells
Groups of 6-to-8-weeks-old C57BL/6 mice (6 mice per group)
were intraperitoneally (i.p.) inoculated with 0.2 ml of suspension
containing 1 × 106 #40a cells in PBS 1 week after pristane
injection (250 µl). Mice were treated i.p. weekly with 20 mg/kg
API (dissolved in DMSO and then diluted in 400 µl PBS).
The control group was injected weekly with the same amount
of vehicle solution (DMSO-PBS). The treatments were started
simultaneously with the inoculation of cells.
Investigation has been conducted in accordance with the
ethical standards and according to the Declaration of Helsinki.
A veterinary surgeon was present during the experiments. The
animal care both before and after the experiments was performed
only by trained personnel. Mice were bred under pathogen-free
conditions in the animal facilities of the University of Rome
“Tor Vergata” and handled in compliance with European
Union and institutional standards for animal research. The
work was conducted with the formal approval of the local
[“Organismo Preposto al Benessere degli animali” (O.P.B.A.),
University of Rome Tor Vergata, http://www.sta.uniroma2.it]
and national (Ministry of Health) animal care committees and
animal experiments have been registered as legislation requires
(Authorization from Ministry of Health n◦ 187/2016-PR).
Analysis of Antitumor Activity In vivo
MM #40a cells growth in the peritoneum forms ascites.
Accordingly, the abdominal circumference of mice was
monitored before the inoculation of cells and every week
until tumor-bearing mice were euthanized at the first signs of
distress or when their abdominal circumference exceeded 12 cm
(Masuelli et al., 2017).
Statistical Analysis
The data distribution of cell survival, cell death, ROS production
and the FACS analyses were preliminarily verified by
Kolmogorov–Smirnov test, and data sets were analyzed by
one-way analysis of variance (ANOVA) followed by Newman-
Keuls test. Differences in the intensity of immunoreactive bands
were evaluated by a two-tailed Student’s t-test. Values with
p ≤ 0.05 were considered significant. Survival curves and tumor
volumes were estimated using the Kaplan–Meier method and
compared with a log-rank test (Mantel-Cox). Differences in
tumor volumes were regarded as significant when the p-value
was ≤0.05 (Benvenuto et al., 2016a; Masuelli et al., 2017).
RESULTS
Cytotoxicity of API on MM Cell Lines
Cell growth of human MM cell lines with different histotypes
[MM-B1 (biphasic), H-Meso-1 (epithelioid), and MM-F1
(fibromatous)] and of a mouse (#40a) MM cell line was
quantified after exposure to increasing doses of Apigenin (API)
(6.25 to 100 µM) or vehicle control for 24, 48, and 72 h by
SRB and Trypan blue exclusion assays. The effect of API was
dose- and time-dependent and reached statistical significance at
the doses 12.5, 25, 50, and 100 µM after 48 and 72 h in all human
cells and at the doses of 25, 50, and 100 µM in #40a cells after
24–72 h of exposure (Figure 1A).
The dye exclusion test was used to determine the number of
viable MM cells upon API exposure. The cytotoxic effect of API
was dose- and time-dependent. The percentage of cell death upon
API treatment was 82, 28 e 9 for MM-B1 (p < 0.001); 78, 41 e 19
for MM-F1 (p< 0.001); 83, 48 e 24 for H-Meso-1 (p< 0.001) cells
and 69, 42 e 18 for #40a (p< 0.001) cells after 72 h of exposure at
the highest doses (Figure 1B).
The concentrations of API required to reduce cell growth
by 50% (IC50) were 49.16 ± 2.52 µM, 46.95 ± 1.69, and
34.31 ± 1.55 µM for MM-B1, MM-F1, and H-Meso-1 after 72 h,
respectively and 56.82 ± 4.69 for #40a after the same time of
exposure (Table 1).
API Induces ROS Generation in MM Cells
and DNA Damage
It was reported that API increases ROS in cancer cells (Wang
and Zhao, 2017). To determine the effect of API on intracellular
ROS production, the DCF-DA assay was performed in API-
treated MM cells. The effect of the compound was compared to
that of DMSO and the results were expressed as the mean of
the fluorescence intensity (Figure 2). API induced a significant
dose-dependent ROS production as compared to the vehicle in
all MM cells. API induced a significant ROS production even at
the lower dose in MM-B1 and MM-F1 cells.
ROS cause DNA damage that rapidly results in the
phosphorylation of the histone H2A variant (H2AX) at Ser 139
(γ-H2AX) (Sharma et al., 2012). Treatment with API at the
concentration of 50 µM for 24 h led to a significant increased
of γ-H2AX in all MM cell lines (MM-F1, p = 0.001; MM-B1,
p = 0.003; H-Meso-1, p = 0.03; #40a, p = 0.005) (Figure 3). The
higher increase of H2AX phosphorylation observed in MM-B1
cells might reflect the behavior of its histotype or the distinctive
expression of DNA repair enzymes in this cell line.
API Activates Apoptosis But Not
Autophagy in MM Cells
Autophagy represents the ability of the cell to adapt to stress.
In order to demonstrate whether API treatment was able to
induce autophagy in MM cell lines, the expression of proteins
involved in autophagy (i.e., Beclin-1, p62/SQSTM, and LC3)
was investigated by Western blotting in API-treated MM cell
lines. As shown in Figure 4, the expression levels of Beclin-1
and p62 remained unchanged in all MM cell lines. During
autophagy, cytosolic LC3-I is modified to a membrane-bound
form (LC3-II) that localizes to autophagosomes, making this
protein an autophagosomal marker (Kabeya et al., 2000). LC3-I
and/or LC3-II were constitutively expressed in DMSO-treated
MM cell lines. API treatment induced a slight significant
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FIGURE 1 | Effect of Apigenin (API) on malignant mesothelioma (MM) cell lines growth and death. (A) The growth of human (MM-B1, H-Meso-1, MM-F1) and mouse
(#40a) MM cell lines were assessed by the SRB assay after 24, 48, and 72 h of treatment with DMSO or API. The percentage of cells growth treated with API was
calculated by normalizing the O.D. value to that of the control cultures (DMSO). The results are expressed as the mean ± SD of three independent experiments
performed in triplicate (xp ≤ 0.05, ∗p ≤ 0.01, #p ≤ 0.001 compared with the cultures treated with DMSO). (B) Trypan blue exclusion test was performed to
determine the percentage of cell death of MM cells treated with API or DMSO after 24, 48, and 72 h of treatment. The results are expressed as the mean ± SD of
three independent experiments performed in triplicate (xp ≤ 0.05, ∗p ≤ 0.01, #p ≤ 0.001 compared with the cultures treated with DMSO).
increase of LC3-II only in MM-F1 cells while a significant
decrease in LC3-II has been shown in #40a cells. These results
suggest that API does not induce autophagy in MM cell lines
(Figure 4).
It was reported that when the stress is too potent, the process
of autophagy is circumvented and the apoptosis is activated
(Mariño et al., 2014). The role of p53 in repressing autophagy and
activating multiple pro-apoptotic genes prompted us to evaluate
p53, Bax, and Bcl-2 expression in MM cells upon API (50 µM
for 24 hours) treatment by Western blotting. Bax expression
was strongly increased in API-treated MM-F1, H-Meso-1 and
#40a cells, while the increase was moderate in MM-B1 cells.
In addition, the expression of Bcl-2 was down-regulated in
MM-F1-treated cells compared to DMSO-treated cells. Thus,
Bax/Bcl-2 ratio increased in MM cell lines treated with API
as compared to cells treated with DMSO (MM-F1, p = 0.017;
MM-B1, p = 0.02; H-Meso-1, p = 0.014; #40a, p = 0.018)
(Figures 5A,C).
Furthermore, API increased p53 expression compared to
DMSO treatment in MM-F1 (p = 0.001), MM-B1 (p = 0.0063),
H-Meso-1 (p = 0.008), and #40a (p = 0.02) cells (Figures 5A,C).
The activation of the intrinsic pathway of the apoptosis is
sustained by the activation of the procaspase 9 into caspase 9
or decrease of procaspase 9 (Wang and Zhao, 2017). API was
able to decrease procaspase 9 expression in MM-F1 and MM-B1
cells as compared to DMSO treated cells (p = 0.0033 and 0.0093,
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TABLE 1 | Apigenin (API) concentrations required for 50% inhibition of malignant
mesothelioma (MM) cell lines growth (IC50).
MM cell lines API treatment (hours) IC50 ± SD (µM)
MM-B1 48 64.23 ± 2.73
72 49.16 ± 2.52
MM-F1 48 56.31 ± 2.13
72 46.95 ± 1.69
H-Meso-1 48 46.44 ± 4.08
72 34.31 ± 1.55
#40a 48 60.39 ± 3.62
72 56.82 ± 4.69
FIGURE 2 | Effect of API on the intracellular ROS production in MM cell lines.
Results are reported as the mean of the fluorescence intensity ± SD values
from three experiments performed in triplicate. API was used in the range
6.25–100 µM. Statistical significance of the effects obtained with API was
calculated vs. those obtained with DMSO (xp ≤ 0.05, ∗p ≤ 0.01, #p ≤ 0.001).
respectively) (Figures 5B,C). The levels of procaspase 9 remained
unchanged in H-Meso-1 and #40a cells.
Next, we determined whether API was able to activate
apoptosis through the extrinsic pathway as well. API activated
procaspase 8 as detected by Western blotting analysis showing
the presence of caspase 8 cleavage fragments (p43/41 and/or p18)
in all treated MM cells (Figure 5B).
The cleavage of poly (ADP-ribose) polymerase-1 (PARP-1)
impairs DNA repairs and genomic integrity sustaining apoptosis,
and is mainly mediated by activation of caspase 3 (Kaufmann
et al., 1993). Thus, API-mediated cleavage of PARP-1 was
analyzed by Western blotting. API treatment induced PARP-1
proteolytic cleavage in all MM cells (Figure 5B).
To further evaluate the effect of API on apoptosis, the analysis
of the cell cycle distribution of API-treated MM cells was
performed by FACS analysis of DNA content. Figure 6, shows a
representative experiment in which the effect of increasing doses
of API on DNA content were compared to that obtained with
DMSO. The mean results of three independent experiments are
reported in Figure 7. Our results demonstrated that API induced
a dose-dependent increase in the percentage of cells in subG1 in
all MM cell lines. The hypodiploid DNA content detected in the
subG1 phase is typical of apoptosis. Such effect was associated
with a decrease of the percentage of cells in G0/G1 in all MM
cell lines and with an increase of the percentage of cells in G2/M
in MM-B1, MM-F1, and #40a cells.
API Decreases EGFR and ErbB2
Expression, Increases the
Phosphorylation of ERK1/ERK2 and p38
But Diminishes that of c-Jun and AKT
ErbB receptors signaling transduction pathway is activated
in mesothelial cells by asbestos (Heintz et al., 2010). Thus,
the expression of EGFR and ErbB2, the expression and
phosphorylation of mitogen-activated protein (MAP) kinases
including ERK1/2, the p38 kinase and the c-Jun N-terminal
kinases (JNKs p54 and p46) were analyzed by Western blotting
after API cells treatment (Figure 8).
The levels of phosphorylated proteins were compared with
the total proteins level. As shown in Figure 8A, API treatment
was able to reduce the expression of EGFR in human MM cells
(MM-F1, p= 0.0091; MM-B1, p= 0.0035; H-Meso-1, p= 0.0014)
and of ErbB2 in human and mouse MM cell lines (MM-F1,
p = 0.013; MM-B1, p = 0.0005; H-Meso-1, p = 0.007; #40a,
p = 0.0024). In addition, treatment with API increased the level
of phosphorylation of ERK1 and ERK2 in MM-B1 (p= 0.009 and
p = 0.001, respectively), H-Meso-1 (p = 0.003 and p = 0.0003,
respectively), and #40a (p = 0.0022 and p = 0.0006, respectively)
cells compared to DMSO-treated cells. Conversely, the effect was
opposite in MM-F1-treated cells (p = 0.022 and p = 0.0009,
respectively). p38 phosphorylation was increased upon API
treatment in MM-F1 (p = 0.0005), MM-B1 (p = 0.002), and
#40a (p = 0.0198) cells. On the other hand, p38 phosphorylation
was decreased in H-Meso-1 (p = 0.024) cells (Figure 8A). p54
JNK phosphorylation was significantly diminished in MM-B1
and H-Meso-1 cells (p = 0.0067 and p = 0.02, respectively) and
it was abolished in #40a cells (p = 0.006) compared to control-
treated cells. p54 JNK phosphorylation was unchanged in MM-B1
cells. p46 JNK phosphorylation was decreased in MM-B1 and
#40a cells (p = 0.005 and p = 0.0033, respectively), while it was
increased in MM-B1 (p = 0.0136) and remained unchanged in
H-Meso-1 cells, compared to control-treated cells (Figure 8B).
Apigenin treatment significantly decreased the expression
of c-Jun in H-Meso-1 as compared to DMSO-treated cells
(p = 0.0004). Of note, a decreased c-Jun phosphorylation was
observed in MM-F1 (p = 0.005), MM-B1 (p = 0.002), and
H-Meso-1 (p = 0.0004) upon API cells treatment (Figure 8B).
c-Jun phosphorylation was not affected by API cells treatment in
#40a cells.
Finally, API cells treatment abolished AKT phosphorylation
in MM-F1 (p = 0.0192) and MM-B1 (p = 0.0031) cells while
increased it in H-Meso-1 (p = 0.012) cells. p-AKT was not
detected in #40a cells (Figure 8B).
API Inhibits NF-κB Nuclear Translocation
Apigenin has been demonstrated to inhibit NF-κB both in vitro
and in vivo in cancer cells (Wu et al., 2014; Shukla et al., 2015). No
results are available on the effect of API on NF-κB in MM cells.
Thus, we determined whether API was able to modulate NF-κB
expression and/or activation in MM cells. Treatment with API
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FIGURE 3 | Effect of API on DNA damage in MM cells. The expression of γ-H2AX was determined by Western blotting analysis in MM cell lines treated with API at
50 µM or with DMSO (CTR) for 24 h. Actin was used as an internal control. The intensity of the bands was quantified using the ImageJ software after blot scanning
of two independent experiments. The densitometric ratios between γ-H2AX and actin and statistical analysis are reported. Data are expressed as the mean ± SD of
two independent experiments (xp ≤ 0.05, ∗p ≤ 0.01 compared with CTR).
did not affect the expression of NF-κB in MM cells as observed
by Western blotting (Figure 9A).
NF-κB acts as a transcription factor, moving into its active
form in the nucleus. The activation of NF-κB is regulated by
phosphorylation and degradation of IκBα. Unphosphorylated
IκBα blocks NF-κB in the cytoplasm while phosphorylated
IκBα is normally ubiquitinated and degraded leaving the
active NF-κB which is then able to translocate into the
nucleus. To determine whether API treatment was able to
affect NF-κB nuclear translocation, we analyzed the expression
and phosphorylation of IκBα by Western blotting and NF-κB
localization by immunofluorescence analysis. Phosphorylation
of IκBα was significantly decreased in API-treated MM-F1 and
H-Meso-1 cells compared to DMSO-treated cells (p = 0.00018
and p = 0.035, respectively) while it was increased in #40a cells
upon API treatment (p = 0.0004) (Figure 9A). In addition,
NF-κB was found to be mainly localized in the nucleus in
DMSO-treated MM cells. Conversely, API treatment induced the
accumulation of NF-κB in the cytoplasm of MM-F1, MM-B1 and
H-Meso-1 cells, but not in #40a cells. This result indicates an
inhibitory effect of API on NF-κB nuclear translocation in human
MM cell lines (Figure 9B).
API Reduces Tumor Growth in C57BL/6
Mice Intraperitoneally Transplanted with
MM #40a Cells
To evaluate the in vivo antitumor effects of API, C57BL/6
mice (6 mice per group) were intraperitoneally inoculated with
1x106 syngeneic MM cells (#40a). Mice were simultaneously
intraperitoneally administered with 20 mg/kg API dissolved in
DMSO-PBS or with the vehicle alone (CTR). The treatment was
performed weekly. Since #40a cells form ascites, the measurement
of the abdominal circumference of the mice was assessed prior to
cells inoculation and then every week. After 2 weeks of treatment,
mice treated with API showed a significant lower abdominal
circumference than control mice (mean value 6.9 cm compared
with 7.8 cm, p= 0.0072) (Figure 10A).
All control mice were euthanized at 5 (three mice) and 6
(three mice) weeks of treatment, for the excessive size of their
tumors. Conversely, all API-treated mice remained alive at this
time (mean abdominal circumference 7.0 cm). API-treated mice
were euthanized at 9 weeks (mouse mouse) and at 12 weeks
(five mice) of treatment.
Overall, when comparing the survival of C57BL/6 mice upon
treatment, it was observed that API treatment prolonged mice
median survival time as compared to the vehicle treatment (12 vs.
5.5 weeks; p= 0.0009) (Figure 10B). The risk of tumor growth in
the vehicle-treated mice was 23.17 relative to API-treated mice
(Table 2). Our results indicated that API specifically interfered
with intraperitoneally transplanted MM #40a cells growth.
DISCUSSION
The survival of MM patients remains poor although
multimodality-approaches including surgery, chemotherapy
and radiation have increased the quality of patient’s life (Favoni
and Florio, 2011). To date Clinicaltrials.gov listed more than
one hundred registered trials worldwide evaluating multiple
therapeutic approaches for MM treatment (ClinicalTrials.gov,
2017). A large number of new drugs have been evaluated in
preclinical studies and early clinical trials in MM patients
(Kotova et al., 2015). In addition, the local administration of
drugs in the peritoneal or pleural space might be an improved
strategy to treat MM. Towards this end, several clinical trials have
been approved for intrapleural delivery of targeted therapy in
pleural MM (ClinicalTrials.gov, 2017). Intra serous sac therapies
are hypothesized to have better antitumor activity because
the agent would be in direct contact with cancer cells and it
could reach higher concentrations by limiting the side effects.
The majority of intracavitary chemotherapy trials have used
platinum-based regimens, but despite the local administration
of the drug side effects occurred (Chang and Sugarbaker,
2004). Intrapleural gene therapy and immunotherapy have
been also employed but these therapies appear to be more
advantageous in patients with small tumors (Gomez and
Tsao, 2014). The combination of targeted therapies has shown
to increase anti-tumor activities (Favoni and Florio, 2011).
A “multifunctional drug” is a molecule able to modulate the
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FIGURE 4 | Effect of API on the autophagic flux in MM cells. The expression of Beclin-1, p62/SQSTM (p62), and LC3-I and LC3-II was assessed by Western blotting
in MM cell lines treated with API at 50 µM or DMSO (CTR) for 24 h. Actin was used as an internal control. The intensity of the bands obtained was quantified using
the ImageJ software after blot scanning of two independent experiments. The densitometric ratios between Beclin-1 and actin, LC3-I and actin, LC3-II and actin,
p62 and actin and statistical analysis are reported. Data are expressed as the mean ± SD of two independent experiments (∗p ≤ 0.01 compared with CTR).
FIGURE 5 | Effect of API on the expression of molecules involved in apoptosis in MM cells. (A) The expression of Bax, Bcl-2, p53 was assessed by Western blotting
analysis in MM cells treated for 24 h with API at 50 µM or with DMSO (CTR) as vehicle. Actin was used as an internal control. (B) The expression of procaspase 9,
procaspase 8, cleaved caspase 8 fragments, and the cleavage of PARP-1 were assessed by Western blotting analysis in MM cells treated for 24 h with API at
50 µM or with DMSO (CTR) as vehicle. Actin was used as an internal control. The intensity of the bands was quantified using ImageJ software after blot scanning,
obtained from two independent experiments. (C) The densitometric ratios between Bax and Bcl-2, between p53 and actin, and between procaspase 9 and actin
and statistical analysis are reported. Data are expressed as the mean ± SD of two independent experiments (xp ≤ 0.05, ∗p ≤ 0.01 compared with CTR).
activity of multiple targets involved in carcinogenesis through
direct interaction or modulation of gene expression (Masuelli
et al., 2014). Polyphenols are considered multifunctional drugs
(Benvenuto et al., 2013; Fantini et al., 2015; Stedile et al.,
2016). We recently demonstrated that the intraperitoneal
administration of curcumin reduced the growth of MM #40a
cells transplanted in the peritoneal cavity of C57BL/6 mice
(Masuelli et al., 2017). Among the others the polyphenol
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FIGURE 6 | Effect of API on cell cycle distribution. FACS analysis of DNA content was performed on asynchronized log phase growing MM cells treated for 48 hours
with DMSO or API at 6.25–100 µM. A representative experiment is shown in the figure.
FIGURE 7 | Stacked bar graphs showing the percentage of cells in different phases of the cell cycle. Percentage of cells in subG1, G0/G1, S, and G2/M phases was
calculated with CellQuest Pro 5.2 software. Results represent mean values from three independent experiments. Statistical significance of the effects obtained with
API treatment was calculated vs. those obtained in DMSO-treated cells with one-way ANOVA analysis of variance (xp ≤ 0.05, ∗p ≤ 0.01, #p ≤ 0.001).
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FIGURE 8 | Effect of API on the expression and activation of signaling pathway molecules. Western blotting analysis was performed on MM cells treated with API
(50 µM) or DMSO (CTR) for 24 h. (A) The levels of pERK1 and pERK2 proteins, as well as p-p38 protein were compared with that of total ERK and p38 proteins,
respectively. (B) The levels of pJNK p54, pJNK p46, p-c-Jun, and pAKT were compared with that of total JNK, c-Jun and AKT proteins, respectively. The ratios and
statistical analysis are reported. Data are expressed as the mean ± SD of two independent experiments (xp ≤ 0.05, ∗p ≤ 0.01, #p ≤ 0.001 compared with CTR).
Actin and tubulin were used as an internal control.
apigenin was shown to have anti-tumoral in vitro activity by
targeting multiple signaling pathways (Lepley and Pelling,
1997; Yin et al., 2001; Ujiki et al., 2006; Shukla and Gupta,
2007; Hussain et al., 2010; Shukla and Gupta, 2010; Masuelli
et al., 2011; Bao et al., 2013; Tong and Pelling, 2013; Chen
et al., 2014; Lee et al., 2014; Wu et al., 2014; Liu et al., 2015;
Seo et al., 2015; Shi et al., 2015; Shukla et al., 2015; Kim et al.,
2016; Lim et al., 2016; Sung et al., 2016; Xu et al., 2016; Ganai,
2017).
Here, we demonstrated for the first time that API treatment
was able to inhibit the growth of MM cell lines in vivo. Indeed,
the intraperitoneal administration of API reduced the growth of
MM #40a cells transplanted in the peritoneal of C57BL/6 mice.
The risk of developing tumors in vehicle treated mice was 23.17
in comparison to those treated with 20 mg/kg API one time
per week. Only few data are available on the in vivo antitumor
activity of API. Budhraja et al. reported the attenuation of tumor
growth in U937 xenografts by API (Budhraja et al., 2012). Shukla
and Gupta showed the induction of p53-mediated apoptosis
in prostate cancer by in vivo API administration (Shukla and
Gupta, 2008). In addition, API has been demonstrated to
synergize with chemotherapeutic agent such as gemcitabine and
5-fluorouracil in vivo (Lee et al., 2008; Hu et al., 2015). API has
been demonstrated to modulate immune response by inhibiting
regulatory T cells (Tregs) and increasing CD4+ and CD8+ T
cells at the tumor site in pancreatic cancer (Nelson et al.,
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FIGURE 9 | Effect of API on NF-κB activation. (A) Western blotting analysis was performed on MM cells treated with API at 50 µM or with the DMSO vehicle (CTR)
for 24 h. The densitometric ratios between NF-κB and actin, IκBα and actin, p-IκBα and IκBα and statistical analysis are reported. Data are expressed as the
mean ± SD of two independent experiments (xp ≤ 0.05, #p ≤ 0.001 compared with CTR). (B) Inhibition of nuclear translocation of NF-κB after treatment with API in
MM cells was assessed by immunofluorescence analysis. Cells were fixed after treatment, and incubated with the anti-NF-κB antibody. After two washes with PBS,
the cells were incubated with the goat anti-mouse IgG Alexa fluor-488-conjugated secondary antibody. Nuclei were stained with DAPI. Original magnification x400.
2017). The presence of Tregs has been demonstrated in MM
microenvironment (Ying et al., 2015). Thus, the use of a drug
that is able to simultaneously modulate immune response and
inhibit cancer cells growth might represent a promising tool for
MM treatment.
Apigenin is a potent pleiotropic molecule being able to
simultaneously inhibit different signaling transduction pathways
(Sung et al., 2016). Thus, the effects of API were also analyzed
in vitro employing human and mouse MM cells. Here we
demonstrate that API induced apoptosis in MM cells. Recent
reports suggest a role for ROS in inducing apoptosis by cells
treatment with several drugs, including chemopreventive agents
(Singh et al., 2005). We demonstrated that API induced ROS
generation resulting in DNA damage and up-regulation of p53.
One of the most characterized mechanisms of API is the ability
to induce apoptosis through the p53-related pathway (Sung et al.,
2016). In addition, it has been demonstrated that API was able to
increase the production of ROS which induced up-regulation of
p53 in prostate cancer and in hepatoma cancer cells (Shukla and
Gupta, 2008; Zhang et al., 2015). Accordingly, we demonstrated
that the increase of p53 expression was paralleled by the
up-regulation of Bax protein expression, the increase in the
Bax/Bcl-2 ratio and the activation of caspase 9 in API-treated MM
cells.
Apigenin is a histone deacetylases (HDAC) inhibitor. HDACs
are emerging as remarkable molecular targets for anticancer
drugs and therapy. HDAC inhibitors (HDACi) induce apoptosis
limiting the function of HDACs, thus declining the levels of
antiapoptotic proteins (Black and Morris, 2012; Ganai, 2017).
Several clinical trials using HDACi alone or in combination
with chemotherapy have been approved for treatment of
human MM. Moreover, HDACi have been demonstrated to
sensitize malignant cells to EGFR inhibition in non-small
cell lung carcinoma (Lindemann et al., 2007). We previously
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FIGURE 10 | Apigenin reduced tumor growth and increased the survival in C57BL/6 mice intraperitoneally transplanted with MM #40a cells. (A) Differences in mean
abdominal circumferences between C57BL/6 mice treated with API or with DMSO-PBS (CTR). (B) Differences in the mean survival duration of C57BL/6 mice treated
with API or with DMSO-PBS (CTR). The numbers of inoculated mice are reported in the Section “Materials and Methods”.
TABLE 2 | Analysis of the survival of C57BL/6 mice after treatment with API by the log-rank test (Mantel-Cox).
Variable Contrast Hazard Ratio 95%Hazard Ratio Confidence Limits Median Survival (weeks) p Value
Lower Upper
Treatment CTR vs API 23.17 3.617 148.4 5.5 vs 12 0.0009
CTR = control; API = apigenin.
demonstrated that API was able to selectively inhibit the
tyrosine phosphorylation of specific residues of EGFR and
ErbB2 in head and neck squamous cell carcinoma (Masuelli
et al., 2011). Here, we demonstrated that API treatment
decreases the expression of both EGFR and ErbB2. This
might be due to API-induced proteasomal degradation through
polyubiquitination as demonstrated for ErbB2/neu (Pandey et al.,
2012). Thus, the use of API can mimic the effects of HDAC
inhibitors and EGFR/ErbB2-TKI in a unique molecule.
In addition, we report that API treatment activates the
extrinsic apoptotic pathway by up-regulating the levels of cleaved
caspase-8 (Liao et al., 2014).
Autophagy can act either as a tumor-suppressor or as a
tumor-promoter (Zhan et al., 2016). Clinical trials are performed
using autophagy inhibitors in combination with other drugs to
treat different types of cancer (Towers and Thorburn, 2016).
We recently demonstrated that treatment with curcumin in
MM cell lines was able to trigger the autophagic flux but
that the process was then blocked to promote MM cells
apoptosis (Masuelli et al., 2017). It has been described that
API is able to activate autophagy in several human cancer
cell lines (Sung et al., 2016). The increased levels of ROS and
DNA damage can activate autophagy via activation of different
signal transduction pathways. However, treatment with API did
not trigger autophagy in our model, despite the inhibition of
AKT phosphorylation. API has been demonstrated to modulate
directly or indirectly several signal transduction pathways
including PI3K/AKT and NF-κB (Ganai, 2017). Recent studies
have reported that the effects of API-mediated down-regulation
of the PI3K/AKT pathways is dependent on the inhibition of
GLUT-1 expression (Bao et al., 2013). Several studies have shown
that AKT regulates the NF-κB pathway via phosphorylation
and activation of molecules of the NF-κB signaling pathway.
Inhibition of activation of IKKα led to a decrease in the
phosphorylation status of IκBα that in its unphosphorylated form
maintains NF-κB blocked in the cytoplasm (Romashkova and
Makarov, 1999; Sarkar and Li, 2004). We demonstrated that API
treatment was able to inhibit nuclear translocation of NF-κB
in all human MM cell lines. This event was paralleled by the
decrease of phosphorylation and/or expression of IκBα, probably
due to inhibition of AKT activation. In addition, the inhibition of
NF-κB activity could induce apoptosis by down-modulating the
expression of its regulated genes including Bcl-2. Overall, API-
mediated-inhibition of NF-κB, and AKT signaling might inhibit
pro-survival signals inducing apoptosis in MM cells.
The effect of API on MAPKs-mediated signaling pathways
remains unclear. Several studies have reported increase or
decrease phosphorylation of MAPKs pathways, depending on
cell type (Kim et al., 2013; Sui et al., 2014; Wu et al., 2015; Lim
et al., 2016). No data are available on the effects of apigenin on
ERK1/2 activation in MM cell lines. Here, we demonstrated that
API treatment was able to increase ERK1/2 phosphorylation in
MM-B1, H-Meso-1, and #40a cells while induced a decrease of
ERK1/2 activation in MM-F1 cells. The opposite effect might
due to different histotypes of the MM cell lines reflecting the
natural tumor heterogeneity occurring in humans. Moreover,
API treatment induced the activation of p38 MAPK in all MM
cells except in H-Meso-1 cells, and the inhibition of JNK p54
in all MM cells with the exception of MM-F1 cells. A decrease
in JNK p46 was also demonstrated in MM-B1 and #40a cell
lines. API has been demonstrated to activate or inhibit both
p38 and JNK pathways depending on cell type (Wu et al., 2015;
Sung et al., 2016). The p38 MAPK is strongly activated by
oxidative and genotoxic stresses and regulates apoptosis, cell cycle
arrest and growth inhibition (Sui et al., 2014). c-Jun N-terminal
kinase (JNK) is also activated in response to a variety of stress
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signals and has been implicated in regulation of apoptosis and
autophagy (Sui et al., 2014). The activated JNK regulates a
variety of transcription factors such as c-Jun and c-Fos. Thus,
API-dependent activation of p38 could mediate the activation of
apoptosis. API-dependent inhibition of JNK by decreasing the
phosphorylation and expression of c-Jun in MM cells resulted in
the inhibition of MM cell growth.
CONCLUSION
Overall, we demonstrated that Apigenin inhibited in vitro
and in vivo malignant mesothelioma cells growth by targeting
different signaling pathways and inducing apoptosis. Our
findings may have important implications for the design of MM
treatment using API in addition to other drugs.
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